Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 9/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474201 | 0.89 | IMPDH2 (0.43) | IMPDH2AAK1 | |
| SCHEMBL6200855 | 0.87 | AAK1 (0.41) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1475193 | 0.87 | IMPDH2 (0.47) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL6172680 | 0.81 | IMPDH2 (0.33) | IMPDH2IMPDH1 | |
| SCHEMBL5630245 | 0.80 | POLB (0.39) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1473137 | 0.79 | IMPDH2 (0.50) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1472763 | 0.77 | IMPDH2 (0.49) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1475774 | 0.76 | IMPDH2 (0.49) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1475940 | 0.75 | AAK1 (0.43) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1473012 | 0.75 | IMPDH2 (0.50) | IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| EP-1126843-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
| EP-1126843-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025780-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885AAK1 2181/4885ROCK2 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.